E Fund Management’s Regenxbio RGNX Stock Holding History

E Fund Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,055	Closed	-$213K	–	349
2022 Q3	$213K	Sell	8,055 -912	-10%	-$27.1K	0.02%	297
2022 Q2	$221K	Buy	+8,967	New	+$224K	0.02%	284

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

E Fund Management's RGNX Position: Q4 2022 in Review

E Fund Management sold out of Regenxbio (RGNX) in Q4 2022, closing a stake of 8,055 shares — an estimated $213K sold.

E Fund Management first reported a position in RGNX in Q2 2022 and held it in 2 quarters. The position peaked at $221K in Q2 2022. 182 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

E Fund Management reported no remaining Regenxbio position as of Q4 2022 after selling out during the quarter.
E Fund Management sold 8,055 Regenxbio shares in Q4 2022, an estimated $213K.
E Fund Management first reported a position in Regenxbio in Q2 2022 and held it in 2 quarters.
E Fund Management's Regenxbio position peaked at $221K in Q2 2022.
182 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on E Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.